RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells

Molecular Cancer Research

Volumn 6, Issue 10, 2008, Pages 1607-1620

  Doublier, Sophie ^a   Riganti, Chiara ^a   Voena, Claudia ^a   Costamagna, Costanzo ^a   Aldieri, Elisabetta ^a   Pescarmona, Gianpiero ^a   Ghigo, Dario ^a,b   Bosia, Amalia ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Sezione di Biochimica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DOXORUBICIN; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; NITRIC OXIDE SYNTHASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; NITRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATASES; AMIDES; CELL DEATH; CELL NUCLEUS; COLONIC NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; GENE SILENCING; HT29 CELLS; HUMANS; KINETICS; L-LACTATE DEHYDROGENASE; MODELS, BIOLOGICAL; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PROTEIN TRANSPORT; PYRIDINES; RHOA GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 54249105822     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0251     Document Type: Article

References (43)

1. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A 1994;91:3497-504.
2. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
3. Baird RD, Kaye SB. Drug resistance reversal-are we getting closer? Eur J Cancer 2003;39:2450-61.
4. Bonadonna G, Monfardini S. Cardiac toxicity of daunorubicin. Lancet 1969;1:837.
5. Fritz G, Kaina B. Rho GTPases: promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 2006;6:1-14.
6. Riganti C, Orecchia S, Pescarmona G, Betta PG, Ghigo D, Bosia A. Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int J Cancer 2006;119:17-27.
7. Dulak J, Józkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 2005;5:579-94.
8. Goldstein LJ. MDR1 expression in solid tumours. Eur J Cancer 1996;32:1039-50.
9. Riganti C, Miraglia E, Viarisio D, et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 2005;65:516-25.
10. Kraynack NC, Corey DA, Elmer HL, Kelley TJ. Mechanism of NOS2 regulation by Rho GTPase signaling in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002;283:L604-11.
11. Rattan R, Giri S, Singh AK, Singh I. RhoA negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKα. Free Radic Biol Med 2003;39:1037-50.
12. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005;30:43-52.
13. 2 in activated murine macrophages. Mol Cell Biol 2000;20:1692-8.
14. Wu C, Ghosh S. Differential phosphorylation of the signal-responsive domain of IκBα and IκBβ by IKB kinases. J Biol Chem 2003;278:31980-7.
15. Yan SR, Joseph RR, Rosen K, et al. Activation of NF-κB following detachment delays apoptosis in intestinal epithelial cells. Oncogene 2005;24:6482-91.
16. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full length cDNA for the human MDR1 gene confers resistance to colchicines, doxorubicin and vinblastine. Proc Natl Acad Sci U S A 1987;84:3004-8.
17. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer line. Science 1992;258:1650-4.
18. Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstein S, Spiegel S. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A 2006;103:16394-9.
19. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Causes Control 2003;10:159-65.
20. Greten FR, Karin M. The IKK/NF-κB activation pathway - a target for prevention and treatment of cancer. Cancer Lett 2004;206:193-9.
21. Lim JH, Lee J-C, Lee YH, et al. Simvastatin prevents oxygen and glucose deprivation/reoxygenation-induced death of cortical neurons by reducing the production and toxicity of 4-hydroxy-2E-nonenal. J Neurochem 2006;97:140-50.
22. Ahn KS, Sethi G, Aggarwal BB. Simvastatin potentiates TNF-α-induced apoptosis through the down-regulation of NF-κB-dependent antiapoptotic gene products: role of IκB-α kinase and TGFβ-activated kinase-1. J Immunol 2007;178:2507-16.
23. Wei CY, Huang KC, Chou YH, Hsieh PF, Lin KH, Lin WW. The role of Rho-associated kinase in differential regulation by statins of interleukin-1β- and lipopolysaccharide-mediated nuclear factor κB activation and inducible nitricoxide synthase gene expression in vascular smooth muscle cells. Mol Pharmacol 2006;69:960-7.
24. Polk WW, Ellis ME, Kushleika JV, Simmonds PL, Woods JS. RhoA regulation of NF-κB activation is mediated by COX-2-dependent feedback inhibition of IKK in kidney epithelial cells. Am J Physiol Cell Physiol 2007;293:C1160-70.
25. Xu H, Liu P, Liang L, et al. RhoA-mediated, tumor necrosis factor α-induced activation of NF-κB in rheumatoid synoviocytes. Inhibitory effect of simvastatin. Arthritis Rheum 2006;54:3441-51.
26. Araki S, Dobashi K, Asayama K, Shirahata A. Simvastatin enhances induction of inducible nitric oxide synthase in 3T3-L1 adipocytes. Free Radic Res 2007;41:1028-34.
27. Foster MW, McMahon TJ, Stamler JS. S-nitrosylation in health and disease. Trends Mol Med 2003;9:160-7.
28. Arlt A, Vorndamm J, Breitenbroich M, et al. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) and doxorubicin. Oncogene 2001;20:859-68.
29. Cusack JC, Liu R, Baldwin AS. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res 2000;60:2323-30.
30. Bentires-Alj M, Barbu V, Fillet M, et al. NF-κB transcription factor induce drug resistance through MDR1 expression in cancer cells. Oncogene 2003;22:90-7.
31. Huang Y, Johnson K, Norris J, Fan W. NF-κB/IκB signalling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000;60:4426-32.
32. Ogretmen B, Safa AR. Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr cells by cross-coupled NF-κB/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry 1999;38:2189-99.
33. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004;104:1825-32.
34. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003;63:1515-19.
35. Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003;545:144-50.
36. Yague E, Higgins CF, Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther 2004;11:1170-74.
37. Pillè JY, Denoyelle C, Varet J, et al. Anti-RhoA and Anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 2005;11:267-74.
38. Pillè JY, Li H, Blot E, et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther 2006;17:1019-26.
39. Aldieri E, Orecchia S, Ghigo D, et al. Simian virus 40 infection downregulates the expression of nitric oxide synthase in human mesothelial cells. Cancer Res 2004;64:4082-84.
40. Guo Z, Shao L, Du Q, Soo Park K, Geller DA. Identification of a classic cytokine-induced enhancer upstream in the human iNOS promoter. FASEB J 2006;21:535-42.
41. Beutler E. Red cell metabolism. A manual of biochemical methods. New York: Grune & Stratton; 1971. p. 56-68.
42. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-59.
43. Gayet L, Dayan G, Barakat S, et al. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. Biochemistry 2005;44:4499-509.